Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
NCT00786305Phase 2Completed
- Sponsor
- La Pitié-Salpêtrière Hospital
- Start
- Oct 2004
- Primary completion
- Sep 2008
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2 trial of ceftazidime and amikacin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by La Pitié-Salpêtrière Hospital. Primary endpoint: Bacterial killing at 14 days. Started Oct 2004; status: completed.
02
Drugs
ceftazidimeamikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT00786305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786305.